
Fermenta Biotech (FERMENTA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.4B
Gross Profit
892.2M
65.48%
Operating Income
224.2M
16.45%
Net Income
216.0M
15.85%
EPS (Diluted)
₹7.47
Balance Sheet Metrics
Total Assets
6.1B
Total Liabilities
2.6B
Shareholders Equity
3.6B
Debt to Equity
0.71
Cash Flow Metrics
Revenue & Profitability Trend
Fermenta Biotech Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 4.7B | 3.3B | 3.5B | 4.0B | 3.7B |
Cost of Goods Sold | 1.6B | 1.4B | 1.6B | 1.7B | 1.4B |
Gross Profit | 3.0B | 1.9B | 1.9B | 2.3B | 2.3B |
Gross Margin % | 65.0% | 57.1% | 53.1% | 58.5% | 61.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 323.8M | 281.5M | 296.2M | 323.2M | 299.7M |
Other Operating Expenses | 793.8M | 610.4M | 620.6M | 650.0M | 522.3M |
Total Operating Expenses | 1.1B | 891.9M | 916.8M | 973.2M | 822.0M |
Operating Income | 933.5M | 94.1M | -10.2M | 391.7M | 668.1M |
Operating Margin % | 20.0% | 2.8% | -0.3% | 9.8% | 18.0% |
Non-Operating Items | |||||
Interest Income | 27.5M | 35.7M | 20.4M | 13.2M | 35.5M |
Interest Expense | 131.9M | 159.4M | 189.9M | 162.7M | 156.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 832.1M | -98.7M | -513.1M | 269.4M | 516.3M |
Income Tax | 68.0M | 141.4M | 18.3M | 118.8M | 91.0M |
Effective Tax Rate % | 8.2% | 0.0% | 0.0% | 44.1% | 17.6% |
Net Income | 764.0M | -240.1M | -531.3M | 150.6M | 425.3M |
Net Margin % | 16.4% | -7.2% | -15.2% | 3.8% | 11.5% |
Key Metrics | |||||
EBITDA | 1.2B | 385.1M | 299.1M | 673.4M | 898.9M |
EPS (Basic) | ₹26.35 | ₹-7.99 | ₹-17.70 | ₹5.35 | ₹15.77 |
EPS (Diluted) | ₹26.35 | ₹-7.99 | ₹-17.70 | ₹5.33 | ₹15.69 |
Basic Shares Outstanding | 29168976 | 28874107 | 28857303 | 28847322 | 28847322 |
Diluted Shares Outstanding | 29168976 | 28874107 | 28857303 | 28847322 | 28847322 |
Income Statement Trend
Fermenta Biotech Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 282.4M | 218.3M | 352.9M | 130.6M | 167.9M |
Short-term Investments | 424.2M | 380.0M | 247.7M | 126.4M | 195.7M |
Accounts Receivable | 952.3M | 698.3M | 416.5M | 872.0M | 680.1M |
Inventory | 1.2B | 873.8M | 1.3B | 1.6B | 1.6B |
Other Current Assets | 331.0K | 160.2M | 4.5M | 34.0K | 33.0K |
Total Current Assets | 3.4B | 2.4B | 2.5B | 3.1B | 3.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.2B | 2.5B | 2.2B | 2.1B | 1.7B |
Goodwill | 112.3M | 153.9M | 363.3M | 395.0M | 424.4M |
Intangible Assets | 30.0M | 71.6M | 132.7M | 176.0M | 210.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 6.2M | 11.7M | 1.0K | 156.0K | 35.8M |
Total Non-Current Assets | 2.8B | 3.1B | 3.8B | 3.9B | 3.8B |
Total Assets | 6.1B | 5.5B | 6.4B | 7.1B | 6.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 774.9M | 649.0M | 457.9M | 645.8M | 621.4M |
Short-term Debt | 954.4M | 906.9M | 1.3B | 1.2B | 1.2B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 9.8M | 11.9M | 1.8M | 2.1M | 4.2M |
Total Current Liabilities | 2.1B | 1.7B | 2.1B | 2.1B | 2.1B |
Non-Current Liabilities | |||||
Long-term Debt | 194.9M | 480.7M | 855.8M | 1.2B | 1.1B |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 140.5M | 139.7M | 150.0M | 50.0M | 3.4M |
Total Non-Current Liabilities | 440.8M | 894.1M | 1.2B | 1.3B | 1.2B |
Total Liabilities | 2.6B | 2.6B | 3.2B | 3.4B | 3.3B |
Equity | |||||
Common Stock | 145.8M | 144.4M | 144.3M | 144.2M | 144.2M |
Retained Earnings | 3.3B | 2.5B | 2.8B | 3.3B | 3.2B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.6B | 2.9B | 3.1B | 3.7B | 3.6B |
Key Metrics | |||||
Total Debt | 1.1B | 1.4B | 2.2B | 2.4B | 2.3B |
Working Capital | 1.2B | 684.9M | 443.0M | 1.1B | 1.0B |
Balance Sheet Composition
Fermenta Biotech Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 832.1M | -98.7M | -513.1M | 269.4M | 516.3M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 0 | 1.9M | -10.2M | 27.0M | 59.2M |
Working Capital Changes | -974.5M | 93.3M | 598.1M | -223.5M | -81.7M |
Operating Cash Flow | -59.5M | 148.8M | 511.9M | 221.3M | 616.7M |
Investing Activities | |||||
Capital Expenditures | -28.8M | -191.4M | -404.4M | -370.4M | -552.6M |
Acquisitions | - | - | - | 0 | -94.4M |
Investment Purchases | - | - | - | - | -22.0M |
Investment Sales | - | - | - | - | 205.5M |
Investing Cash Flow | -28.8M | -191.4M | -404.4M | -370.4M | -485.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -36.1M | -36.1M | -42.0M | -72.1M | - |
Debt Issuance | 0 | 30.5M | 363.1M | 243.0M | 291.7M |
Debt Repayment | -358.2M | -504.7M | -539.6M | -212.3M | -150.0M |
Financing Cash Flow | -394.5M | -728.5M | -195.6M | -35.4M | 177.4M |
Free Cash Flow | 187.7M | 861.4M | 756.2M | 63.1M | 73.3M |
Net Change in Cash | -482.8M | -771.1M | -88.1M | -184.5M | 308.7M |
Cash Flow Trend
Fermenta Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
9.13
Price to Book
2.66
Price to Sales
1.81
PEG Ratio
-0.02
Profitability Ratios
Profit Margin
19.81%
Operating Margin
16.45%
Return on Equity
21.44%
Return on Assets
12.51%
Financial Health
Current Ratio
1.58
Debt to Equity
32.06
Beta
-0.16
Per Share Data
EPS (TTM)
₹35.83
Book Value per Share
₹123.23
Revenue per Share
₹180.57
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
fermenta | 9.8B | 9.13 | 2.66 | 21.44% | 19.81% | 32.06 |
Sun Pharmaceutical | 4.0T | 37.73 | 5.42 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 67.57 | 10.40 | 14.64% | 23.89% | 0.03 |
Innova Captab | 48.6B | 37.44 | 5.07 | 13.37% | 9.98% | 35.24 |
Suven Life Sciences | 48.0B | -28.31 | 41.36 | -146.15% | 84.44% | 0.00 |
Gujarat Themis | 46.2B | 103.15 | 18.55 | 19.64% | 30.17% | 12.27 |
Financial data is updated regularly. All figures are in the company's reporting currency.